InDaily

Adelaide's independent news

Support

Mayne Pharma shares rise over US deal

Business

Mayne Pharma shares have soared 19 per cent to a near five-month high, after the Adelaide-based pharmaceutical company inked an exclusive long-term deal to sell a new contraceptive drug in the United States.

Print article

The ASX-listed drugs manufacturer announced on Wednesday it had signed a 20-year supply and licence agreement with Belgium-based Mithra Pharmaceuticals to commercialise a “next generation” contraceptive pill.

Seeking a bigger slice of an American market deemed to be worth $US5.4 billion, Mayne Pharma will pay up to $US295 million ($A440 million) in cash and shares if net sales of the drug exceed $US2.25 billion ($A3.36 billion).

Shares in the South Australian company had spiked 18.87 per cent to 63 cents on the ASX by 1120 AEST.

The drug E4/DRSP, which contains 15mg estetrol (E4) and 3mg drospirenone, could lead to improved patient outcomes among America’s 10 million women who use short-acting hormonal contraceptives.

It was tested on 3,725 women during the third stage of clinical studies, producing positive top-line results.

Mithra has developed a method to produce E4, a native estrogen created by the human foetal liver during pregnancy, at scale through a plant-based process after more than 20 years of research and development.

The new pill is expected to be rolled out in first half of 2021, subject to US regulatory approval, in what would be a historic feat.

“If approved, estetrol (E4) will be the first native estrogen approved in a contraceptive product in the US and the first new estrogen introduced in the US in approximately 50 years,” Mayne chief executive Scott Richards said.

Richards expects E4/DRSP to be a “foundation asset” in women’s health for years to come.

“Women’s health is a core therapeutic area for the company and this deal enables Mayne Pharma to accelerate and extend its position in this specialty,” he said.

It also strengthens ties between Mayne and Mithra, as they simultaneously target approval for a generic contraceptive ring next year.

-AAP

We value local independent journalism. We hope you do too.

InDaily provides valuable, local independent journalism in South Australia. As a news organisation it offers an alternative to The Advertiser, a different voice and a closer look at what is happening in our city and state for free. Any contribution to help fund our work is appreciated. Please click below to become an InDaily supporter.

Powered by PressPatron

More Business stories

Loading next article

Subscribe to InDaily – it’s free!

South Australia’s locally owned, independent source of digital news.

Subscribe now and go in the monthly draw* for your chance to WIN a $100 voucher!

Subscribe free here

*Terms and conditions apply

Welcome back!

Did you know it’s FREE to subscribe?

Subscribe now and go in the monthly draw* for your chance to WIN a $100 voucher!

Subscribe

*Terms and conditions apply